Please login to the form below

Not currently logged in
Email:
Password:

cardiovascular diseases

This page shows the latest cardiovascular diseases news and features for those working in and with pharma, biotech and healthcare.

Merck KGaA inks deal for Medisafe adherence app

Merck KGaA inks deal for Medisafe adherence app

It is the first time the two companies have worked together and the initial project will cover drugs for type 2 diabetes, thyroid disorders and cardiovascular diseases.

Latest news

  • AZ adds another Ionis drug in $330m kidney disease deal AZ adds another Ionis drug in $330m kidney disease deal

    which started clinical trials in solid tumours last year, and AZD8233 for cardiovascular disease whose target is being kept under wraps for now. ... This is the second drug to enter development under our strategic collaboration with AstraZeneca in

  • Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ

    In a statement the French pharma group’s chief executive - Olivier Brandicourt - said the deal “enhances its presence in specialty care and leadership in rare diseases”and will make the company ... Towards the end of last year, it showcased its R&D

  • After some big setbacks, Sanofi talks up its R&D portfolio After some big setbacks, Sanofi talks up its R&D portfolio

    Meanwhile, ten pivotal phase III trials due to start in the next 12 months in its core therapeutic areas of immunology and multiple sclerosis, oncology, diabetes/cardiovascular, vaccines and rare diseases.

  • Sanofi launches French eHealth laboratory 39BIS Sanofi launches French eHealth laboratory 39BIS

    Sanofi’s eHealth strategy in France is focused on healthcare professionals - including dispensing pharmacists - and medicines, pharmacovigilance, skin disorder diagnosis and exploring diagnostics in rare diseases and vaccines. ... In France, we already

  • EU’s 10-year paediatric meds report - not bad, but can do better EU’s 10-year paediatric meds report - not bad, but can do better

    diseases. “In diseases that are rare and/or unique to children and which in many cases are equally supported through the orphan legislation, major therapeutic advances often failed to materialise, ”says ... The bulk of paediatric investigation plans

More from news
Approximately 5 fully matching, plus 86 partially matching documents found.

Latest Intelligence

  • Finding the patient voice Finding the patient voice

    rheumatoid arthritis, oncology, psychiatry, cardiovascular diseases, rare diseases etc.

  • Deal Watch December 2016 Deal Watch December 2016

    1, 850. Bicycle (UK). AstraZeneca (UK). Licence collaboration. Bicycle platform: small molecules with antibody specificity for targets in respiratory, cardiovascular and metabolic diseases. ... 320. Evotec (Germany). Celgene (US). Discovery collaboration.

  • A healthy challenge A healthy challenge

    Vytenis told PME he is “ very concerned” about the rising burden of chronic non-communicable diseases, such as cardiovascular diseases, cancer and type 2 diabetes. “ ... The risk of developing these diseases is very much increased due to some of

  • Opening up innovation Opening up innovation

    For GlaxoSmithKline its pharma open innovation efforts began with diseases of the developing world, such as malaria - where it offered researchers free access to a 'virtual library' of tens of thousands ... With over 1, 000 potential products being

  • Cost containment and the German market Cost containment and the German market

    Apart from growing revenues from innovative drugs, the sales volumes of medicine for highly prevalent and chronic diseases like cardiovascular indications are expected to increase due to the demographic development. ... Biopharmaceuticals have become

More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.

Latest appointments

  • MyoKardia appoints COO and medical affairs VP MyoKardia appoints COO and medical affairs VP

    Prior to this, Dr Lee was therapeutic area head for cardiovascular, metabolic, respiratory and infectious disease programmes at Genentech. ... Meanwhile, Dr Tripuraneni (pictured left) brings over 10 years of medical affairs expertise in a variety of

  • Cardio3 BioSciences appoints Warren Sherman chief medical officer Cardio3 BioSciences appoints Warren Sherman chief medical officer

    therapy and other treatments for cardiovascular diseases.”. ... for the further development of Cardio3 BioSciences' future projects in regenerative therapies and cardiovascular diseases.”.

  • Pfizer appoints diabetes expert Morris Birnbaum Pfizer appoints diabetes expert Morris Birnbaum

    Pfizer appoints diabetes expert Morris Birnbaum. He takes up post as chief scientific officer for cardiovascular and metabolic diseases. ... Pfizer has appointed prominent academic Dr Morris Birnbaum as chief scientific officer for its research into

  • INC Research appoints Dr Martin Sullivan INC Research appoints Dr Martin Sullivan

    INC Research has appointed Dr Martin Sullivan as its new executive director for cardiovascular medicine. ... Sally Osmond, general manager of cardiovascular and endocrinology clinical development at INC Research, said: "The prevalence of cardiovascular

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles

With a network of more than 27,000 employees conducting business in approximately 100 countries, we have helped develop or commercialize...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics